Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Wells

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 19, 2008
Fluorescent 7-diethylaminocoumarin pyrrolobenzodiazepine conjugates: synthesis, DNA interaction, cytotoxicity and differential cellular localizationGeoffrey Wells, Marie Suggitt, Marissa Coffils, et al.
Journal of Medicinal Chemistry|January 22, 2005
Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agentsJane M Berry, Tracey D Bradshaw, Iduna Fichtner, et al.
Communications Biology|May 15, 2021
Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanismYuta Horie, Takafumi Suzuki, Jin Inoue, et al.
Journal of Medicinal Chemistry|August 1, 2008
Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648)Stefania Aiello, Geoffrey Wells, Erica L Stone, et al.
Journal of Medicinal Chemistry|January 5, 2022
Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral SclerosisOlmo Martín-Cámara, Marina Arribas, Geoffrey Wells, et al.
ACS Chemical Biology|March 27, 2026
Structural Studies of βTrCP Reveal Plasticity in Binding Modes of Consensus and Nonconsensus DegronsGavin W Collie, Hazel Mak, Marta Acebrón-García-de-Eulate, et al.
BMJ Supportive & Palliative Care|July 19, 2022
Cancer centre supportive oncology service: health economic evaluationEleanor Stewart, Simon Tavabie, Caroline McGovern, et al.
Nature Reviews. Drug Discovery|January 6, 2019
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseasesAntonio Cuadrado, Ana I Rojo, Geoffrey Wells, et al.
Journal of Medicinal Chemistry|May 13, 2022
Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding ModeNikolaos Georgakopoulos, Sandeep Talapatra, Dina Dikovskaya, et al.
Cancer Research|May 4, 2005
Elucidation of thioredoxin as a molecular target for antitumor quinolsTracey D Bradshaw, Charles S Matthews, Jennifer Cookson, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|February 19, 2008
Fluorescent 7-diethylaminocoumarin pyrrolobenzodiazepine conjugates: synthesis, DNA interaction, cytotoxicity and differential cellular localizationGeoffrey Wells, Marie Suggitt, Marissa Coffils, et al.
Journal of Medicinal Chemistry|January 22, 2005
Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agentsJane M Berry, Tracey D Bradshaw, Iduna Fichtner, et al.
Communications Biology|May 15, 2021
Molecular basis for the disruption of Keap1-Nrf2 interaction via Hinge & Latch mechanismYuta Horie, Takafumi Suzuki, Jin Inoue, et al.
Journal of Medicinal Chemistry|August 1, 2008
Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648)Stefania Aiello, Geoffrey Wells, Erica L Stone, et al.
Journal of Medicinal Chemistry|January 5, 2022
Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral SclerosisOlmo Martín-Cámara, Marina Arribas, Geoffrey Wells, et al.
ACS Chemical Biology|March 27, 2026
Structural Studies of βTrCP Reveal Plasticity in Binding Modes of Consensus and Nonconsensus DegronsGavin W Collie, Hazel Mak, Marta Acebrón-García-de-Eulate, et al.
BMJ Supportive & Palliative Care|July 19, 2022
Cancer centre supportive oncology service: health economic evaluationEleanor Stewart, Simon Tavabie, Caroline McGovern, et al.
Nature Reviews. Drug Discovery|January 6, 2019
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseasesAntonio Cuadrado, Ana I Rojo, Geoffrey Wells, et al.
Journal of Medicinal Chemistry|May 13, 2022
Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding ModeNikolaos Georgakopoulos, Sandeep Talapatra, Dina Dikovskaya, et al.
Cancer Research|May 4, 2005
Elucidation of thioredoxin as a molecular target for antitumor quinolsTracey D Bradshaw, Charles S Matthews, Jennifer Cookson, et al.
Pageof 5